UBS Raises Amgen (AMGN) Target as Pharma and Biotech Setup Improves [Yahoo! Finance]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Yahoo! Finance
On January 26, UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock. The call reflects a more constructive view on the broader US pharma and biotech space. UBS expects the group to hold up well this year. Valuations are still appealing, investor positioning remains light, and some of the pressure around drug pricing has started to ease. Add in steady pharma-led M&A activity, which often spills over into biotech, and the setup looks supportive. Even with worries that guidance could turn cautious after the recent rally, UBS argues that big pharma and biotech still look cheap enough to keep money flowing into the sector. Earlier this month, Amgen CEO Bob Bradway spoke with CNBC's Jim Cramer and shared his optimism around the company's obesity drug. He said long-term weight management is one of the hardest challenges in this space, and that is where Amgen believes it can make a difference. On January 12, Amgen said a trial of it
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Steve Jobs' son says he can help end cancer deaths - and he's raising millions to do it [Yahoo! Finance]Yahoo! Finance
- Amgen (NASDAQ:AMGN) was given a new $400.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have an "outperform" rating on the stock.MarketBeat
- AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTSPR Newswire
- Amgen Set to Report Q4 Earnings: What Investors Should Know [Yahoo! Finance]Yahoo! Finance
- TransCelerate BioPharma Showcases Approaches to Advancing Clinical Trial Efficiency and Patient-Centered Design at SCOPE US 2026 [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 11/4/25 - Beat
AMGN
Sec Filings
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- AMGN's page on the SEC website